10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q2 2020

Filing Information

Form Type	10-Q
Accession Number	`0001493152-20-014178`
Period End Date	20200630
Filing Date	20200729
Fiscal Year	2020
Fiscal Period	Q2
XBRL Instance	ocx-20200630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 81 Income Statement 68 Cash Flow Statement 90 Comprehensive Income 12

Balance Sheet 81 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.03M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$22.07M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$35.83M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$16.80M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$79.00K	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$341.00K	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$379.00K	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	150.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$505.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.23M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	150.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$22.96M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$18.45M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	57.03M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	67.22M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	57.03M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	67.22M	shares	Point-in-time
Right-of-use assets, machinery and equipment, net	`RightofuseAssetsMachineryAndEquipmentNet`	$3.73M	USD	Point-in-time
Right-of-use assets, machinery and equipment, net	`RightofuseAssetsMachineryAndEquipmentNet`	$4.39M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$10.96M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$14.33M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	-	USD	Point-in-time
Intangibles, net	`IntangibleAssetsNetExcludingGoodwill`	$15.05M	USD	Point-in-time
Intangibles, net	`IntangibleAssetsNetExcludingGoodwill`	-	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$2.05M	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$2.21M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$39.86M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$63.45M	USD	Point-in-time
Amount due to Lineage and affiliates	`DueToRelatedPartiesCurrent`	-	USD	Point-in-time
Amount due to Lineage and affiliates	`DueToRelatedPartiesCurrent`	$6.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.16M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$469.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.61M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$3.82M	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	$1.12M	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	$1.48M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`RightofuseAndFinancingLeaseLiabilitiesCurrent`	$376.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`RightofuseAndFinancingLeaseLiabilitiesCurrent`	$230.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.44M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$6.84M	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.91M	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$2.62M	USD	Point-in-time
Financing lease and right of use liabilities, noncurrent	`RightofuseAndFinancingLeaseLiabilitiesNoncurrent`	$3.11M	USD	Point-in-time
Financing lease and right of use liabilities, noncurrent	`RightofuseAndFinancingLeaseLiabilitiesNoncurrent`	$2.68M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	-	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$11.13M	USD	Point-in-time
Deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	$158.00K	USD	Point-in-time
Deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	-	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$23.86M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$9.02M	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 150,000 shares authorized; 67,218 and 57,032 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$150.18M	USD	Point-in-time
Common stock, no par value, 150,000 shares authorized; 67,218 and 57,032 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$124.58M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-110.58M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-93.75M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$39.59M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$36.62M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$33.51M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$38.19M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$30.84M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$3.42M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$39.86M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$63.45M	USD	Point-in-time

Income Statement 68 line items

Line Item	Tag	Value	Unit	Period
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	-	USD	1 Quarter
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$143.00K	USD	1 Quarter
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$158.00K	USD	2 Qtrs
Total revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	-	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$365.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	-	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	-	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$538.00K	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.51M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.38M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.85M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.23M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.76M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$3.64M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$6.08M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$8.38M	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$523.00K	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$318.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$3.05M	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$1.56M	USD	1 Quarter
Total costs and operating expenses	`OperatingExpenses`	$9.46M	USD	2 Qtrs
Total costs and operating expenses	`OperatingExpenses`	$17.36M	USD	2 Qtrs
Total costs and operating expenses	`OperatingExpenses`	$5.46M	USD	1 Quarter
Total costs and operating expenses	`OperatingExpenses`	$8.91M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-9.46M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-17.20M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-5.46M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-8.77M	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNet`	$-97.00K	USD	2 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNet`	$-75.00K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNet`	$147.00K	USD	2 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNet`	$167.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-88.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$90.00K	USD	2 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$16.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-38.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-630.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-301.00K	USD	1 Quarter
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	$30.00K	USD	2 Qtrs
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	$20.00K	USD	1 Quarter
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	-	USD	1 Quarter
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	$-25.00K	USD	2 Qtrs
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-340.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$79.00K	USD	1 Quarter
Total other income (expenses), net	`NonoperatingIncomeExpense`	$212.00K	USD	2 Qtrs
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-735.00K	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-17.93M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-5.38M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-9.25M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-9.11M	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.09M	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-9.25M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-16.84M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-5.38M	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.19	USD	2 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.14	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.10	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.26	USD	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	65,833.00	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	49,324.00	shares	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	63,628.00	shares	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	51,973.00	shares	1 Quarter

Cash Flow Statement 90 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-9.25M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-16.84M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.38M	USD	1 Quarter
Depreciation expense	`Depreciation`	$127.00K	USD	2 Qtrs
Depreciation expense	`Depreciation`	$67.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$84.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$194.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$37.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	-	USD	2 Qtrs
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	-	USD	2 Qtrs
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$301.00K	USD	2 Qtrs
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	2 Qtrs
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$422.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-630.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-301.00K	USD	1 Quarter
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	$67.00K	USD	2 Qtrs
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	$18.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$701.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$1.39M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$1.36M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$2.30M	USD	2 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-88.00K	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$90.00K	USD	2 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$16.00K	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-38.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$57.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$22.00K	USD	2 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	2 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-1.09M	USD	2 Qtrs
Other	`OtherOperatingActivitiesCashFlowStatement`	-	USD	2 Qtrs
Other	`OtherOperatingActivitiesCashFlowStatement`	$26.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$85.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	-	USD	2 Qtrs
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-6.00K	USD	2 Qtrs
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-2.10M	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$540.00K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$889.00K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.06M	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$767.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.56M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-13.87M	USD	2 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireEquityMethodInvestments`	-	USD	2 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireEquityMethodInvestments`	$6.19M	USD	2 Qtrs
Equity method investment in Razor	`PaymentsForEquityMethodInvestment`	$4.00M	USD	2 Qtrs
Equity method investment in Razor	`PaymentsForEquityMethodInvestment`	-	USD	2 Qtrs
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$18.00K	USD	2 Qtrs
Purchase of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$535.00K	USD	2 Qtrs
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	$54.00K	USD	2 Qtrs
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	$43.00K	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$36.00K	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-10.68M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	-	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$943.00K	USD	2 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$18.34M	USD	2 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$40.25M	USD	2 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$31.00K	USD	2 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$3.25M	USD	2 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	-	USD	2 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$14.00K	USD	2 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$125.00K	USD	2 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$400.00K	USD	2 Qtrs
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$35.00K	USD	2 Qtrs
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$227.00K	USD	2 Qtrs
Proceeds from PPP loan	`ProceedsFromLoans`	$1.14M	USD	2 Qtrs
Proceeds from PPP loan	`ProceedsFromLoans`	-	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$19.28M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$37.31M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$27.79M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-5.28M	USD	2 Qtrs
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$35.83M	USD	Point-in-time
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$18.50M	USD	Point-in-time
At beginning of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.03M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$35.83M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$18.50M	USD	Point-in-time
At end of the period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.03M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$45.00K	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$27.00K	USD	2 Qtrs
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	$5.00M	USD	2 Qtrs
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	-	USD	2 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$11.13M	USD	2 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	-	USD	2 Qtrs
Holdback liability	`HoldbackLiability`	-	USD	2 Qtrs
Holdback liability	`HoldbackLiability`	$600.00K	USD	2 Qtrs
Equipment purchases included in accounts payable and accrued liabilities	`EquipmentPurchasesIncludedInAccountsPayableAndAccruedLiabilities`	-	USD	2 Qtrs
Equipment purchases included in accounts payable and accrued liabilities	`EquipmentPurchasesIncludedInAccountsPayableAndAccruedLiabilities`	$180.00K	USD	2 Qtrs

Comprehensive Income 12 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-9.25M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-16.84M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-5.38M	USD	1 Quarter
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	2 Qtrs
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	1 Quarter
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	2 Qtrs
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-9.11M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-16.84M	USD	2 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-9.25M	USD	2 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-5.38M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.